179 related articles for article (PubMed ID: 14966683)
1. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
2. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
3. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
5. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
[TBL] [Abstract][Full Text] [Related]
6. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
Sakai H
Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
[TBL] [Abstract][Full Text] [Related]
7. [P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer].
Soussi T; Peyrat JP; Lubin R; Bonneterre J
Pathol Biol (Paris); 1996 Apr; 44(4):232-4. PubMed ID: 8763583
[TBL] [Abstract][Full Text] [Related]
8. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
9. [Clinical importance of serum anti-p53 antibodies as tumor markers].
Sakai H; Okamoto E
Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
[TBL] [Abstract][Full Text] [Related]
10. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
[TBL] [Abstract][Full Text] [Related]
11. Ethnicity delineates different genetic pathways in malignant glioma.
Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
[TBL] [Abstract][Full Text] [Related]
12. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
[TBL] [Abstract][Full Text] [Related]
14. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.
Trivers GE; De Benedetti VM; Cawley HL; Caron G; Harrington AM; Bennett WP; Jett JR; Colby TV; Tazelaar H; Pairolero P; Miller RD; Harris CC
Clin Cancer Res; 1996 Oct; 2(10):1767-75. PubMed ID: 9816128
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
[TBL] [Abstract][Full Text] [Related]
16. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot.
Schlichtholz B; Legros Y; Gillet D; Gaillard C; Marty M; Lane D; Calvo F; Soussi T
Cancer Res; 1992 Nov; 52(22):6380-4. PubMed ID: 1423285
[TBL] [Abstract][Full Text] [Related]
17. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
18. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
19. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the anti-p53 antibody response in cancer patients.
Labrecque S; Naor N; Thomson D; Matlashewski G
Cancer Res; 1993 Aug; 53(15):3468-71. PubMed ID: 8339249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]